Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

Status:
Recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.

Phase 2

Massachusetts General Hospital

Incyte Corporation